Analysts Expect Neon Therapeutics Inc (NASDAQ:NTGN) Will Post Earnings of -$0.81 Per Share

Equities research analysts expect Neon Therapeutics Inc (NASDAQ:NTGN) to announce ($0.81) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Neon Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.75) and the lowest estimate coming in at ($0.87). Neon Therapeutics posted earnings of ($7.84) per share in the same quarter last year, which would suggest a positive year over year growth rate of 89.7%. The firm is scheduled to report its next quarterly earnings results on Monday, August 5th.

According to Zacks, analysts expect that Neon Therapeutics will report full-year earnings of ($2.69) per share for the current financial year, with EPS estimates ranging from ($3.33) to ($1.83). For the next financial year, analysts forecast that the company will report earnings of ($2.63) per share, with EPS estimates ranging from ($4.26) to ($1.84). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Neon Therapeutics.

Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.03).

NTGN has been the subject of several analyst reports. Mizuho set a $21.00 price target on shares of Neon Therapeutics and gave the stock a “buy” rating in a research report on Monday, July 1st. Zacks Investment Research raised shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Tuesday. Berenberg Bank reduced their price objective on shares of Lucara Diamond from C$1.60 to C$1.50 in a research note on Wednesday, March 27th. Morgan Stanley reduced their price objective on shares of Neon Therapeutics from $19.00 to $13.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating on shares of NioCorp Developments in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $16.00.

Institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace North America L.P. bought a new position in Neon Therapeutics during the 1st quarter worth approximately $49,000. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Neon Therapeutics by 100.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,000 shares of the company’s stock valued at $65,000 after buying an additional 5,000 shares in the last quarter. Rhumbline Advisers bought a new position in Neon Therapeutics in the first quarter valued at approximately $78,000. Bank of New York Mellon Corp lifted its stake in Neon Therapeutics by 17.6% in the fourth quarter. Bank of New York Mellon Corp now owns 19,427 shares of the company’s stock valued at $98,000 after buying an additional 2,905 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Neon Therapeutics by 42.7% in the fourth quarter. Bank of America Corp DE now owns 21,712 shares of the company’s stock valued at $109,000 after buying an additional 6,493 shares in the last quarter. 69.57% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:NTGN traded down $0.56 during trading on Friday, hitting $3.57. 345,529 shares of the company’s stock were exchanged, compared to its average volume of 191,000. Neon Therapeutics has a 1-year low of $3.49 and a 1-year high of $13.00. The company’s 50-day moving average is $4.67. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.30 and a current ratio of 7.30. The company has a market capitalization of $117.01 million and a price-to-earnings ratio of -0.64.

About Neon Therapeutics

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Recommended Story: How to Trade Using Analysts Ratings

Get a free copy of the Zacks research report on Neon Therapeutics (NTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neon Therapeutics (NASDAQ:NTGN)

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.